부산대학교 도서관

It has been well described during the first waves of this disease that COVID-19, the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with worse outcomes (i.e. higher risk of death or intensive care unit [ICU] admission) in patients with cancer [[1]], especially those with hematological malignancies [[3], [5]]. Sixteen patients (64%, among whom 2 patients just received their last treatment before being tested positive for SARS-CoV-2) were receiving first-line treatment. The five remaining patients were a- or pauci-symptomatic since a median of 15 days from the diagnosis of SARS-COV-2 at the time of scheduled chemotherapy (which included rituximab for one patient) and therefore did not have a delay in treatment. Twenty-one patients (84%) were symptomatic for a median duration of 13 days (range 2-43), the most frequent symptoms being cough (16 patients, 64%) and fever (11 patients, 44%). [Extracted from the article]